BCR Human shRNA Plasmid Kit (Locus ID 613)

Specifications

Product Data
Locus ID	613
Synonyms	ALL; BCR1; CML; D22S11; D22S662; PHL
Vector	pRFP-C-RS
E. coli Selection	Chloramphenicol (34 ug/ml)
Mammalian Cell Selection	Puromycin
Format	Retroviral plasmids
Kit Components	BCR - Human, 4 unique 29mer shRNA constructs in retroviral RFP vector(Gene ID = 613). 5µg purified plasmid DNA per construct 29-mer scrambled shRNA cassette in pRFP-C-RS Vector, TR30015, included for free.
RefSeq	NM_004327, NM_021574, NM_004327.1, NM_004327.2, NM_004327.3, NM_021574.1, NM_021574.2, BC031568, BC041705, BC053641, BC063619, BC066122, BC071742, BC083493, BC169208, NM_021574.3, NM_004327.4
UniProt ID	P11274
Summary	A reciprocal translocation between chromosomes 22 and 9 produces the Philadelphia chromosome, which is often found in patients with chronic myelogenous leukemia. The chromosome 22 breakpoint for this translocation is located within the BCR gene. The translocation produces a fusion protein which is encoded by sequence from both BCR and ABL, the gene at the chromosome 9 breakpoint. Although the BCR-ABL fusion protein has been extensively studied, the function of the normal BCR gene product is not clear. The unregulated tyrosine kinase activity of BCR-ABL1 contributes to the immortality of leukaemic cells. The BCR protein has serine/threonine kinase activity and is a GTPase-activating protein for p21rac and other kinases. Two transcript variants encoding different isoforms have been found for this gene.[provided by RefSeq, Jan 2020]
shRNA Design	These shRNA constructs were designed against multiple splice variants at this gene locus. To be certain that your variant of interest is targeted, please contact tech@clinisciences.com. If you need a special design or shRNA sequence, please utilize our custom shRNA service.
Performance Guaranteed	OriGene guarantees that the sequences in the shRNA expression cassettes are verified to correspond to the target gene with 100% identity. One of the four constructs at minimum are guaranteed to produce 70% or more gene expression knock-down provided a minimum transfection efficiency of 80% is achieved. Western Blot data is recommended over qPCR to evaluate the silencing effect of the shRNA constructs 72 hrs post transfection. To properly assess knockdown, the gene expression level from the included scramble control vector must be used in comparison with the target-specific shRNA transfected samples. For non-conforming shRNA, requests for replacement product must be made within ninety (90) days from the date of delivery of the shRNA kit. To arrange for a free replacement with newly designed constructs, please contact Technical Services at tech@clinisciences.com. Please provide your data indicating the transfection efficiency and measurement of gene expression knockdown compared to the scrambled shRNA control (Western Blot data preferred).